<DOC>
	<DOCNO>NCT01562990</DOCNO>
	<brief_summary>The purpose study determine recommend dose CMC544 administer combination rituximab ( R-CMC544 ) , alternance rituximab , gemcitabine oxaliplatin ( R-GEMOX ) first phase study . After , efficacy safety combination evaluate preliminarily patient DLBCL relapse refractory , candidate autologous transplant .</brief_summary>
	<brief_title>Phase Ib/II Study Efficacy Safety R-CMC544/R-GEMOX Combination Diffuse Lage B-cell Lymphoma First Second Relapse</brief_title>
	<detailed_description>This study multicenter , phase Ib/II , open-label , single arm trial evaluate efficacy safety R-CMC544 alternate R-GEMOX patient CD20 CD22 positive DLBCL relapse after/refractory 1st 2nd line treatment , candidate autologous transplant . The study consist 2 phase . In part 1 ( potential dose de-escalation phase ) subject enrolled fix dose CMC544 . In case occurrence dose limit toxicity ( DLT ) , cohorts 3 6 subject evaluate de-escalating dose CMC544 combination set dose rituximab , gemcitabine oxaliplatin order obtain MTD recommend dose CMC544 regimen . In part 2 ( dose expansion phase ) safety preliminary efficacy data propose combination analyze . All patient receive two 56 day induction cycle alternate R-CMC544 ( give day 1 ) R-GEMOX ( give day 29 43 ) . Patients obtain CR PR , go consolidation another two 56 day cycle alternate R-CMC544 ( give day 1 ) R-GEMOX ( give day 29 43 ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Histologically document CD20 CD22 positive diffuse large Bcell lymphoma , accord WHO classification . CD20 CD22 immunophenotyping initial diagnosis acceptable . If prior documentation available , immunophenotyping relapse must establish fineneedle aspirate biopsy circulate CD20 CD22 positive NHL cell peripheral blood screening . Upon registration pathological report confirm diagnosis , must available In first second relapse refractory first and/or second line treatment . Refractory define exhibit less PR prior rituximab contain regimen relapse within 6 month last dose prior rituximab contain regimen . Measurable disease bidimensional transverse CT scan assessment Not eligible autologous transplantation . Previously treat chemotherapy regimen contain anthracyclines rituximab . Aged 18 80 year . ECOG performance status 0 2 . Minimum life expectancy 3 month . Signed write informed consent . Burkitt , mantle cell Tcell lymphoma . Central nervous system meningeal involvement lymphoma . Contraindication drug contain RGEMOX combination chemotherapy . Treatment investigational drug within 30 day first plan cycle chemotherapy study . Nitrosurea mitomycin C administration within 6 week prior study start . Major debulking surgery within 3 week treatment . Any following lab abnormality ( unless relate lymphoma bone marrow infiltration ) : Absolute neutrophil count ( ANC ) &lt; 1.500/µL ( 1,5.109/L ) . Platelet count &lt; 100.000/µL ( 100.109/L ) . Creatinin level &gt; 150 µmol/L ( 1,7 mg/dL ) 1,5 2,0x ULN . Total bilirubin level &gt; 30 µmol/L ( 1,8 mg/dL ) 1,5x ULN . Serum AST/SGOT ALT/SGPT &gt; 2,5x ULN . Documented infection HIV , active hepatitis B C infection . Any serious active disease comorbid medical condition , accord investigator 's decision , substantially increase risk associate subject 's participation study . Prior history malignancy lymphoma exception nonmelanoma skin tumor ( basal cell squamous cell carcinoma skin ) stage 0 ( situ ) cervical carcinoma unless subject diseasefree 5 years.. LVEF le 50 % ( measure echocardiography scintigraphy ) . Previous myocardial infarction pulmonary hypertension within 6 month first dose investigational product . Congestive heart failure NYHA stage III IV Known chronic liver disease ( eg . Cirrhosis ) suspect alcohol abuse . Pregnant lactate female Men woman biologically capable child willing use adequate method birth control study 18 month last dose investigational product . Adult patient unable provide inform consent intellectual impairment , serious medical condition , laboratory abnormality psychiatric illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>